Latest News and Press Releases

FDA has granted Enochian an INTERACT meeting for its innovative approach to autologous stem cell transplantation as a potential cure for HIV. INTERACT is the first available FDA interaction and is a...

LOS ANGELES, Feb. 03, 2020 (GLOBE NEWSWIRE) -- Enochian Biosciences, a company focused on gene-modified cellular therapy in infectious diseases and cancer, announces that it has finalized the...

- Gregg Alton, the former interim CEO of Gilead Sciences, a company he served in many key roles during his more than 20 year tenure, and; - Carol Brosgart, MD, Clinical Professor of Medicine at the...

A new gene therapy kills up to 98 percent of HBV infected cells but not uninfected cells.  Results from a commonly used mouse model to study HBV confirmed the HBV-infected cell-specific killing effect...

Agreement provides Enochian with exclusive rights to develop and commercialize a HBV treatment with a novel mechanism of actionAbstract accepted highlighting the in vivo and in vitro data from...

LOS ANGELES, June 03, 2019 (GLOBE NEWSWIRE) -- Enochian Biosciences, Inc. (Nasdaq: ENOB), a biotechnology company developing potentially curative and preventative genetically modified cellular and...

LOS ANGELES, March 08, 2019 (GLOBE NEWSWIRE) -- Enochian Biosciences, Inc. (Nasdaq: ENOB), et bioteknologiselskab, der udvikler potentielt helbredende og forebyggende, genetisk modificerede...

Enochian developing ENOB-HV-01 an autologous cell therapy as a potentially curative treatment for HIV LOS ANGELES, March 07, 2019 (GLOBE NEWSWIRE) -- Enochian Biosciences, Inc. (Nasdaq: ENOB), a...

LOS ANGELES, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Enochian Biosciences, Inc. (“Enochian”) a biopharmaceutical company focused on the development and commercialization of novel therapies for HIV/AIDS...

– Appoints former President of GSK Global Vaccine business, Luc Debruyne, to Board of Directors – – Advances ENO-1001 for HIV by entering into research collaboration with Scripps Research –...